| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM.2108 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nm.2108 |
| P932 | PMC publication ID | 2834806 |
| P698 | PubMed publication ID | 20173754 |
| P5875 | ResearchGate publication ID | 41510457 |
| P50 | author | Bette Korber | Q30505218 |
| Barton Haynes | Q4865631 | ||
| Will Fischer | Q54215194 | ||
| Mark Muldoon | Q55136070 | ||
| Harikrishnan Balachandran | Q61985835 | ||
| George N Pavlakis | Q87860694 | ||
| Hua-Xin Liao | Q88608388 | ||
| Sampa Santra | Q88772993 | ||
| Norman L. Letvin | Q98917684 | ||
| P2093 | author name string | Barbara K Felber | |
| James Theiler | |||
| Angela Carville | |||
| Keith G Mansfield | |||
| Robert J Parks | |||
| Sydeaka Watson | |||
| Chun-Yen Tsao | |||
| James Szinger | |||
| Ruijin Zhang | |||
| David Quinn | |||
| Adam Buzby | |||
| P2860 | cites work | SYFPEITHI: database for MHC ligands and peptide motifs | Q29616214 |
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| Challenges in the development of an HIV-1 vaccine | Q34657290 | ||
| Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses | Q35851778 | ||
| Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses | Q36229406 | ||
| An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 | ||
| Progress and obstacles in the development of an AIDS vaccine | Q36662462 | ||
| A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys | Q36789752 | ||
| Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination | Q37099729 | ||
| Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses | Q37285535 | ||
| T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces | Q37333743 | ||
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
| Reconstruction of a pathway of antigen processing and class II MHC peptide capture. | Q40151915 | ||
| Coping with viral diversity in HIV vaccine design: a response to Nickle et al. | Q42979227 | ||
| Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. | Q51926211 | ||
| Capacity of intact proteins to bind to MHC class II molecules | Q69741058 | ||
| HIV vaccines | Q82900063 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 324-328 | |
| P577 | publication date | 2010-02-21 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | |
| P478 | volume | 16 |
| Q61805548 | A PRRSV GP5-Mosaic vaccine: Protection of pigs from challenge and ex vivo detection of IFNγ responses against several genotype 2 strains |
| Q27024614 | A global approach to HIV-1 vaccine development |
| Q58593288 | A high throughput lentivirus sieving assay identifies neutralization resistant Envelope sequences and predicts in vivo sieving |
| Q34593969 | A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects |
| Q31148797 | Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques |
| Q35826681 | An HIV Vaccine for South-East Asia-Opportunities and Challenges |
| Q35739123 | Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines |
| Q36760169 | Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 |
| Q36437672 | Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models |
| Q36211653 | Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization |
| Q36638450 | Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens |
| Q89977102 | Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost |
| Q30207890 | Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene |
| Q38065391 | Broadly neutralizing antibodies against HIV-1: templates for a vaccine |
| Q89686737 | CD8+ T cells in HIV control, cure and prevention |
| Q26865388 | Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? |
| Q34423446 | Challenges in the design of a T cell vaccine in the context of HIV-1 diversity |
| Q34059543 | Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer |
| Q35760486 | Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost |
| Q35046349 | Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques |
| Q37530466 | Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. |
| Q35927376 | Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using Peptide block entropy |
| Q36467153 | Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine |
| Q47093684 | Conserved HIV Epitopes for an Effective HIV Vaccine |
| Q37790058 | Considerations in the design of vaccines that induce CD8 T cell mediated immunity |
| Q36414604 | Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. |
| Q33855306 | Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection |
| Q34502108 | Current progress in the development of a prophylactic vaccine for HIV-1. |
| Q30397595 | Current views on the potential for development of a HIV vaccine |
| Q38581981 | DNA Immunization for HIV Vaccine Development |
| Q37395174 | DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. |
| Q58711069 | DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination |
| Q59357834 | DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses |
| Q30410411 | Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications |
| Q34440836 | Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage |
| Q42220600 | Designing the epitope flanking regions for optimal generation of CTL epitopes. |
| Q38619108 | Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses |
| Q40047250 | Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies |
| Q33694226 | Development of replication-competent viral vectors for HIV vaccine delivery |
| Q34792987 | Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors |
| Q36414547 | Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages |
| Q41922147 | Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence |
| Q37870313 | Electroporation delivery of DNA vaccines: prospects for success |
| Q24597625 | Emerging targets and novel approaches to Ebola virus prophylaxis and treatment |
| Q36015624 | Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome |
| Q36978452 | Enhancing poxvirus vectors vaccine immunogenicity. |
| Q28822525 | Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine |
| Q35218117 | Evaluating potential T-cell epitope peptides for detecting HIV-specific T cell responses in a highly diverse HIV-1 epidemic from Cameroon |
| Q50335281 | Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. |
| Q35665770 | For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection |
| Q34464743 | Fragmentation of SIV-gag vaccine induces broader T cell responses |
| Q41579160 | Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys |
| Q56999671 | Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes |
| Q59358201 | Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques |
| Q40354550 | Graph-based optimization of epitope coverage for vaccine antigen design |
| Q35826742 | HIV DNA Vaccine: Stepwise Improvements Make a Difference |
| Q47094945 | HIV Env conserved element DNA vaccine alters immunodominance in macaques |
| Q35227007 | HIV vaccine research: the challenge and the way forward |
| Q39117522 | HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population |
| Q38210557 | HIV vaccines: a brief overview. |
| Q45378201 | HIV vaccines: mosaic approach to virus diversity |
| Q37851950 | HIV vaccines: progress to date. |
| Q40348395 | HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells |
| Q40168307 | HIV-1 Epitope Variability Is Associated with T Cell Receptor Repertoire Instability and Breadth |
| Q36079913 | HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice |
| Q30425520 | HIV-1 Vaccine Trials: Evolving Concepts and Designs |
| Q34388606 | HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques |
| Q34653619 | HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice |
| Q34243456 | HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form |
| Q36767899 | HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection. |
| Q82718989 | HIV-1: from escapism to conservatism |
| Q26765966 | HIV-Host Interactions: Implications for Vaccine Design |
| Q36606741 | Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains |
| Q40054979 | How germinal centers evolve broadly neutralizing antibodies: the breadth of the follicular helper T cell response. |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q42732010 | IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA. |
| Q37789347 | Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection |
| Q39363660 | Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection |
| Q50043326 | Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates. |
| Q37123506 | Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac |
| Q34699353 | Impaired memory CD8 T cell responses against an immunodominant retroviral cryptic epitope |
| Q38009870 | Improved outlook on HIV-1 prevention and vaccine development |
| Q36756865 | Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition |
| Q28741616 | Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences |
| Q37547472 | Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q34540645 | Induction of immunity to human immunodeficiency virus type-1 by vaccination |
| Q37221575 | Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages |
| Q89609089 | Innovations in HIV-1 Vaccine Design |
| Q34055991 | Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials |
| Q37919894 | Intradermal naked plasmid DNA immunization: mechanisms of action |
| Q35043547 | Is developing an HIV-1 vaccine possible? |
| Q38662319 | Justification for the inclusion of Gag in HIV vaccine candidates |
| Q36839817 | Lessons learned from HIV-1 vaccine trials: new priorities and directions |
| Q90009470 | Mathematical model of broadly reactive plasma cell production |
| Q28728189 | Measurements of immune responses for establishing correlates of vaccine protection against HIV |
| Q35276750 | Mechanisms and factors that influence high frequency retroviral recombination |
| Q42269255 | Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells |
| Q33775626 | Mutational escape in HIV-1 CTL epitopes leads to increased binding to inhibitory myelomonocytic MHC class I receptors |
| Q34274849 | New approaches to design HIV-1 T-cell vaccines |
| Q36223864 | New prospects for a preventive HIV-1 vaccine |
| Q47112156 | Novel Concepts for HIV Vaccine Vector Design |
| Q36951283 | Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection |
| Q37668399 | Novel HIV vaccine strategies: overview and perspective |
| Q34257640 | Novel adenovirus vector-based vaccines for HIV-1. |
| Q34541191 | Novel vaccine vectors for HIV-1. |
| Q37094429 | Polyvalent AIDS vaccines |
| Q39108740 | Polyvalent vaccine approaches to combat HIV-1 diversity |
| Q34290973 | Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy |
| Q36083061 | Preparing for the availability of a partially effective HIV vaccine: some lessons from other licensed vaccines |
| Q64080897 | Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus |
| Q37785949 | Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. |
| Q36252761 | Priming Cross-Protective Bovine Viral Diarrhea Virus-Specific Immunity Using Live-Vectored Mosaic Antigens |
| Q35862305 | Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population |
| Q56970600 | Progress in HIV vaccine development |
| Q56600657 | Progress in HIV-1 vaccine development |
| Q27693849 | Progress in HIV-1 vaccine development. |
| Q38534943 | Prospects for a globally effective HIV-1 vaccine |
| Q41924718 | Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine |
| Q37355237 | Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys |
| Q26766628 | Recent update in HIV vaccine development |
| Q37134971 | Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production |
| Q35873940 | Reverse vaccinology: developing vaccines in the era of genomics |
| Q100429973 | Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study |
| Q34742502 | Simian immunodeficiency virus SIVmac239Deltanef vaccination elicits different Tat28-35SL8-specific CD8+ T-cell clonotypes compared to a DNA prime/adenovirus type 5 boost regimen in rhesus macaques |
| Q36452155 | Strategies for eliciting HIV-1 inhibitory antibodies |
| Q91609981 | Strategies for inducing effective neutralizing antibody responses against HIV-1 |
| Q34760497 | Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design |
| Q90479100 | T cell-based strategies for HIV-1 vaccines |
| Q35765737 | The HIV-1 epidemic: low- to middle-income countries |
| Q34358831 | The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection |
| Q34077543 | The influence of delivery vectors on HIV vaccine efficacy |
| Q38011653 | Therapeutic live vaccines as a potential anticancer strategy. |
| Q44419356 | Tiny steps towards an HIV vaccine |
| Q33680395 | Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing |
| Q43040073 | Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation |
| Q92756238 | Use of a Novel Enhanced DNA Vaccine Vector for Preclinical Virus Vaccine Investigation |
| Q36487887 | Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083 |
| Q30411492 | Vaccine design for CD8 T lymphocyte responses |
| Q35073079 | Vaccines that stimulate T cell immunity to HIV-1: the next step |
| Q21089599 | Vaccines: from empirical development to rational design |
| Q30469621 | Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection |
Search more.